In contrast to younger populations, NPM1-mutated AML confers a favorable prognosis in older AML patients ≥ 65 years old, who experience durable treatment-free remission with the above-mentioned time-limited regimen (CAVEAT study) [73]. This evidence concerns the gene NPM1 and acute myeloid leukemia.